Skip to main content

Table 2 Overview of primary and secondary outcomes

From: Impact of timing of continuous intravenous anesthetic drug treatment on outcome in refractory status epilepticus

  Early cIVADs
(n = 53)
Late cIVADs
(n = 24)
Unadjusted RR (95% CI) P value for unadjusted RR Adjusted RRb
(95% CI)
P value for adjusted RR
Primary outcome
 Good outcome at last follow-up 23 (44.2)a 4 (17.4)a 2.543 (0.992–6.521) 0.052 3.175 (1.273–7.918) 0.013
Secondary outcomes
 Good outcome at discharge 13 (24.5) 2 (8.3) 2.943 (0.720–12.037) 0.133 3.985 (0.874–18.161) 0.074
 In-hospital mortality 14 (26.4) 5 (20.8) 1.268 (0.515–3.119) 0.605 1.086 (0.446–2.645) 0.856
 RSE termination 45 (84.9) 21 (87.5) 0.970 (0.803–1.172) 0.970 0.980 (0.803–1.197) 0.980
 Induction of burst suppression 32 (60.4) 22 (91.7) 0.659 (0.513–0.845) 0.001 0.661 (0.507–0.861) 0.002
 Use of thiopental 9 (17.0) 11 (45.8) 0.370 (0.177–0.774) 0.008 0.446 (0.205–0.974) 0.043
 Development of SRSE 30 (56.6) 18 (75.0) 0.775 (0.543–1.050) 0.095 0.769 (0.567–1.093) 0.153
  1. aOne episode lost to follow-up
  2. bAdjusted for Status Epilepticus Severity Score and a potentially fatal etiology
  3. Data in columns 2 and 3 are number (percentage)
  4. Abbreviations: CI confidence interval, cIVAD continuous intravenous anesthetic drug, RR risk ratio, RSE refractory status epilepticus, SRSE super-refractory status epilepticus